Articles On Global Health (ASX:GLH)

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Creso Pharma (CPH) is looking to change its name to Melodiol Global Health to reflect its growth strategyAlso as part of this strategy, Creso welcomes two new directors to its board following the resignation of Non-Executive Director and Fo...

ASX cannabis shares have leapt back onto investor radars and are likely to grab more media headlines in the weeks ahead. While all three are deep in the red today amid wider selling action that sees the All Ordinaries Index (ASX: XAO) down...

A potential takeover of Ramsay Healthcare’s (RHC) 50:50 subsidiary, Ramsay Sime Darby Health Care, will not go aheadIHH Healthcare Berhad had made a conditional, non-binding indicative proposal to acquire the business in March, however, IHH...

In times of great uncertainty the Australian healthcare sector can offer investors plenty of choice, with varying degrees of risk and opportunities. -Australia’s healthcare sector has seen record government investment-Global pandemic has ac...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Global Health (GLH) secures a contract with the Yarram District Health Service to provide various solutions to the hospital and community health services in Yarram, Victoria This contract win is the first for FY22/23 and it is also the fir...

Ansell announces net zero commitment by 2040 Emyria extends its library of novel MDMA-like compounds  to >125 Genetic Technologies partners with Melbourne based Siles Health Protective personal equipment Ansell (ASX:ANN) has just annou...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Merewether C...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Highlights Global Health has inked two key contracts with Homeless Healthcare and Peninsula Health. The contracts build on the healthcare firm’s momentum and existing relationships in Western Australia and Victoria. The contracts have...

ShareCafeAustralia’s Impact on the U.S. Infant Milk Powder Crisis The share prices in both Bubs Australia (ASX: BUB) and a2 Milk (ASX: A2M) have been soaring on the back of news that they can provide aid to the current supply shortage in th...

Global Health (GLH) secures three new contracts with Arcadia Healthcare, Matilda Nepean Private Hospital, and Waikiki Private Hospital to implement a range of its solutions The contracts represent a total value of $185,400 in annual recurr...

Actor and cannabis farmer Jim Belushi is headlining the Grow Up Conference and Expo next month Franchise Global Health has established the first legal seedbank in Denmark Botanix nabs FDA Qualified Infection Disease Product designation for...

The interest rate rise came and the markets fell, then turned a corner. The question now is — will the wheels stay on? Already lagging, the ASX Emerging Companies (XEC) index has closed 0.8% lower. The benchmark has closed 0.4% behind. The...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Opyl’s contracts with two new clinical trial customers have validated the company’s pivot to focus on AI technology and its recruitment platform, Opin. Digital health company Opyl (ASX:OPL) has just signed two new clinical trial recruitment...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two million people. Treasurer Josh Frydenberg announced last night that Australia’s health budget will top $132bn in 2022-23, up from $62bn a decade...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Exchange Traded Funds (ETFs) on the ASX have grown to a $126.9 billion industry. Here’s a guide on the ASX ETF sector and what investors need to know.    Key points ETFs are managed funds, listed on stock exchanges that invest in various f...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Highlights Telehealth companies allow patients to connect with their doctors and medical practioners via phone, messages, or video conference. COVID-19 pandemic gave a boost to the demand for telehealth services. DOC and GLH are two p...

Many sectors of society might have come to a complete halt during COVID-19 if it was not for innovative solutions from the tech industry, which will last well beyond the pandemic. As governments worldwide have been forced to protect public...

Dimerix’s lead drug candidate DMX-200 has been given regulatory green light for approval for a Phase 3 study in COVID-19 ravaged India. Clinical-stage biotech Dimerix (ASX:DXB)  has received approval from the review committee in India for...

Shares in Dimerix Ltd (ASX: DXB) are soaring today, shooting up 9% in early trade. At the time of writing, the Dimerix share price has retreated slightly and is now trading at 30 cents apiece, up 7.4%. Below we take a look at the clinical-...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

23 Aug 2021 - Global Health Care giant Sonic Healthcare (ASX:SHL), delivered significant revenue and earnings for the period ending 30 Jun 2021, amid the Covid-19 pandemic.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

The ASX ended the week on a high note, finishing up 0.13 per cent with most sectors in positive territory. The index touched a record high of 7,334 today but failed to keep the momentum and eventually closed at 7,312. For the week, the inde...

The ASX had a positive trading day finishing nearly 0.5 per cent up with almost all sectors in positive territory. The ASX 200 closed at 7,303 – 0.44 per cent higher than yesterday while the ASX Emerging Companies Index rose over 1 per cent...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Biotech Global Health (ASX:GLH) topped this week’s Running Hot list, in the wake of more steady gains in May which has seen its share price rise by almost 500 per cent over the past 12 months. Each week, Stockhead recaps ASX stocks that are...

Last year's pandemic put the focus firmly on telehealth services providers, but share prices have deflated since as investors started asking questions, and on the general realisation telehealth has its limits too. -Covid-19 triggered a rush...

If you thought the COVID-19 telehealth boom was big, you ain’t seen nothing yet. Telehealth adoption in Australia and around the globe exploded last year due to COVID-19. Specifically, many patients requiring health services were left no ot...

Summary With the current emergency, it is anticipated that telehealth or telemedicine could be the future of medicine. COVID-19 pandemic resulted in considerable adoption of telehealth solutions, mainly to avoid physical contact. The...

Stockhead’s Hot Money Monday analysis is based on the Relative Strength Index (RSI) — a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the level at which a company may have been...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...